Diffuse midline glioma, H3 K27-altered
MONDO:1060171A diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.
Also known as: DMG, H3 K27-altered
3087 clinical trials for this condition and its sub-types, 11 tagged with Diffuse midline glioma, H3 K27-altered itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse midline glioma, H3 K27-altered
-
Diffuse midline glioma, H3 K27M-mutant 31 trials
-
New hope for kids with rare cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called avapritinib in 29 children aged 2 to 18 with advanced solid tumors that have specific genetic changes (KIT or PDGFRA). The goal was to see if the drug is safe and can shrink or control the tumors. Participants took the drug by mouth, and researcher…
Phase 1/2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise in early trial for kids with deadly brain cancer
Disease control CompletedThis early-phase study tested an experimental drug called INCB7839 in 13 children whose high-grade gliomas (aggressive brain tumors) had come back or worsened after standard treatment. The main goals were to find a safe dose and check for side effects. The drug works by blocking …
Phase 1 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC